Emvision Medical Devices Ltd. · ASX:EMV
Emvision Medical Devices — Morgans Scone Value in the Vines Conference 2021
17 slides from Emvision Medical Devices's conference presentation, Oct 21, 2021
Slide 1: EMVision Presenting at Morgans Scone Value in the Vines Conference
21/10/21 EMVision Medical Devices Ltd ACN 620 388 230 Level 10, 12 Creek Street, Brisbane Qld 4000 02 8667 5337 contact@emvision.com.au For personal use only EMVISION PRESENTING AT MORGANS SCONE VALUE IN THE VINES CONFERENCE EMVision Medical Devices Limited (ASX:EMV) (“EMVision” or the “Company”), a
Slide 2: Forward-looking statements
which EMvision operates, and its beliefs and assumptions. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates", "guidance" and similar expressions are intended to identify forward looking statements and should be considered an at-risk statement. Such statement
Slide 3: EMV:ASX Value in the Vines
www.emvision.com.au For personal use only EMV:ASX Value in the Vines ASX:EMV 73.09M $9.7M $8M $4.20 $2.97* $217M* $207.3M* * Undiluted market cap based on closing price of $2.97 20th October 2021
Slide 4: Disclaimer
DISCLAIMER For personal use only This presentation has been prepared by EMVision Medical Devices Limited (“EMVision” or “the Company”). This presentation is not a financial product or investment advice or recommendation, offer or invitation by any person or to any person to sell or purchase securiti
Slide 5: EMVision Is Creating a World First Portable Brain Scanner
EMVISION IS CREATING A WORLD FIRST PORTABLE BRAIN SCANNER For personal use only Neuroimaging as is accessible today EMV 1ST Gen, Neuroimaging anywhere www.emvision.com.au 3 Device under development and subject to clinical validation
Slide 6: Bringing Neuroimaging to the Patient, Wherever They Are
BRINGING NEUROIMAGING TO THE PATIENT, WHEREVER THEY ARE For personal use only FAST – 30 SECOND SCAN TIME AFFORDABLE – COST EFFECTIVE SAFE – NO IONIZING RADIATION AI POWERED – DECISION SUPPORT PORTABLE – CART ULTRASOUND SIZE BEDSIDE - MONITORING ACCESSIBLE – EASY TO OPERATE FIRST CLINICAL USE – STROK
Slide 7: Bringing Imaging to Where Stroke Occurs Will Save Lives
BRINGING IMAGING TO WHERE STROKE OCCURS WILL SAVE LIVES For personal use only STROKE IS A GLOBAL SOCIETAL THERE ARE EFFECTIVE & HEALTH ECONOMIC BURDEN TREATMENTS AVAILABLE THEY ARE TIME SENSITIVE WHAT CLINICIANS NEED TO KNOW… 1 ST GENERATION DEVICE Detect clinically significant changes, at the bedsi
Slide 8: Unmet Need for Pre-Hospital and Bedside Imaging
UNMET NEED FOR PRE-HOSPITAL AND BEDSIDE IMAGING WHERE THERE ARE NO ALTERNATIVE SOLUTIONS READILY ACCESSIBLE 15 mins to 2.5 hours < 2.5 hours < 3 hours < 24 hours <24 hours - 3 weeks <3 weeks - 3 years+ For personal use only Stroke Onset A TYPICAL PATIENT Pre-hospital Hospital ED CT Image Studies Int
Slide 9: Challenges with Traditional Neuroimaging in Hospitals
CHALLENGES WITH TRADITIONAL NEUROIMAGING IN HOSPITALS For personal use only GOLD STANDARD NEUROIMAGING DEVICES, CT AND MRI, PROVIDE EXCELLENT IMAGES BUT ARE FOR THE MOST PART, STATIONARY COMPLEX INFRASTRUCTURE REQUIREMENTS; SPECIALIST OPERATORS AND HIGH-COSTS LIMITS THEIR ACCESSIBILITY UP TO 40% ADV
Slide 10: Estimated Portable Brain Scanner Potential Financial Benefits to a Public Hospital
E S T I M AT E D P O R TA B L E B R A I N S C A N N E R P OT E N T I A L F I N A N C I A L B E N E F I T S TO A P U B L I C H O S P I TA L I N A U S T R A L I A * For personal use only Estimated Annual Total Financial Benefit of one Reduction in Transportation Costs $120,000 device (excluding annual
Slide 11: More Lives Could Be Saved with a Lightweight Scalable Imaging Solution
M O R E L I V E S C O U L D B E S AV E D W I T H A L I G H T W E I G H T S C A L A B L E I M A G I N G S O L U T I O N W I T H T E L E M E D I C I N E C A PA B I L I T I E S For personal use only Mobile Stroke Unit management results in substantially less disability for stroke patients who qualify f
Slide 12: Technology Overview
TECHNOLOGY OVERVIEW For personal use only EXAMPLE OF IMAGE PROCESSING Array of antennas send pulses of low-power electromagnetic waves into the head Co-Registration 1 Waves penetrate tissue in a non-ionizing and harmless manner and get scattered based on the 2 electrical properties of tissue Algorit
Slide 13: Very Encouraging Outcomes from Foundational Clinical Study
VERY ENCOURAGING OUTCOMES FROM FOUNDATIONAL CLINICAL STUDY For personal use only Examples of EMVision (EMV) Brain Scanner imaging vs. Standard-of-Care (SOC) imaging in 6 Patients THE EMVISION TECHNOLOGY WAS TRIALLED ON STROKE PATIENTS FOR THE FIRST TIME IN 2020 AT THE PRINCESS ALEXANDRA HOSPITAL, BR
Slide 14: Clinical Investigations Roadmap
CLINICAL INVESTIGATIONS ROADMAP CY 22 H1 H2 For personal use only CLINICAL INVESTIGATIONS ROADMAP 1ST GEN DEVICES PRE-VALIDATION – SITE 1-2 CENTRES: MULTI CENTRE LOCATION: EMERGENCY DEPARTMENT (ED) & WARDS UNDERGOING Patient total # to be enrolled TBC: Anticipated ~ 100-300 VERIFICATION AND 1. Preli
Slide 15: Flexible & Attractive Revenue Models
FLEXIBLE & ATTRACTIVE REVENUE MODELS DIRECT OR DISTRIBUTOR For personal use only MONTHLY SUBSCRIPTION MODEL CAPITAL EQUIPMENT & CONSUMABLES MODEL Delivery of the unit Consumables Training Device Sales Software updates Target - ~$150,000 USD New algorithm sequences as they come out Software Potential
Slide 16: Team
TEAM Significant experience developing and commercialising medical devices For personal use only Dr Ron Weinberger John Keep Scott Kirkland Prof Stuart Crozier Robert Tiller Forough Khandan CEO & MD Non-Executive Chairman Executive Director Chief Scientific Officer Head of Design Head of Product Dev
Slide 17: Capital Structure
CAPITAL STRUCTURE For personal use only Headquarters: Management, Directors and Founders hold approximately 20% SIGNIFICANT PROGRESS 4.01, 65 Epping Road, Macquarie Park HAS BEEN HAVE BEEN Sydney, Australia Top 20 holds approximately 35% ACHIEVED AND MILESTONES MET WITH A Top 100 holds approximately
EMVision Medical Devices — Morgans Scone Value in the Vines Conference 2021 on 6ix